TME Pharma N.V. (ALTME.PA)
Company Info
Highlights
€8.05M
-€0.12
-€66.00K
-€5.17M
€0.06 - €0.15
€0.61
Share Price Chart
Loading data...
Compare to other instruments
Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.
Performance
Performance Chart
Loading data...
Returns By Period
TME Pharma N.V. (ALTME.PA) returned 11.73% year-to-date (YTD) and -45.19% over the past 12 months.
ALTME.PA
11.73%
15.59%
4.88%
-45.19%
-73.73%
-71.52%
N/A
^GSPC (Benchmark)
2.58%
1.25%
-0.67%
11.07%
17.97%
14.15%
11.08%
Monthly Returns
The table below presents the monthly returns of ALTME.PA, with color gradation from worst to best to easily spot seasonal factors. Returns are adjusted for dividends.
| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Total | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2025 | -6.40% | 2.56% | -10.69% | 0.47% | 28.79% | 0.72% | 11.73% | ||||||
| 2024 | -0.00% | 36.33% | 0.17% | -18.79% | 1.16% | -41.84% | -3.93% | 12.37% | -16.64% | 18.47% | -7.21% | -32.25% | -56.27% |
| 2023 | -6.84% | 10.37% | -18.31% | 53.54% | -10.08% | -13.34% | 15.23% | 11.07% | -20.07% | -69.60% | -21.64% | -14.80% | -79.13% |
| 2022 | -1.03% | -22.71% | -12.01% | -33.46% | -2.67% | -47.55% | -9.90% | -10.16% | -19.19% | -4.77% | -56.49% | -16.16% | -94.80% |
| 2021 | -24.47% | 4.12% | -2.04% | 1.43% | -4.60% | -9.26% | -6.31% | -11.57% | -3.49% | -6.64% | -9.37% | -9.02% | -58.36% |
| 2020 | -14.09% | -23.80% | -9.45% | 75.36% | 6.61% | -11.63% | -15.88% | 7.82% | 1.93% | -33.59% | 58.86% | 1.08% | -3.44% |
| 2019 | -14.71% | -4.02% | -0.60% | -12.89% | 5.12% | -16.32% | -12.89% | -10.20% | -3.52% | -8.33% | -17.84% | 61.00% | -42.94% |
| 2018 | -18.11% | 13.46% | -27.12% | 11.16% | -43.10% | -25.74% | -12.38% | 32.20% | 2.56% | -25.83% | -15.17% | -32.45% | -83.94% |
| 2017 | -1.73% | 0.09% | 1.25% | 0.00% | -20.55% | -5.17% | -15.15% | -12.14% | -12.60% | -24.65% | -14.81% | -7.97% | -71.12% |
| 2016 | 2.28% | -2.27% | 2.33% | 2.28% |
Risk-Adjusted Performance
Risk-Adjusted Performance Rank
The current rank of ALTME.PA is 23, meaning it’s performing worse than 77% of other stocks on our website when it comes to balancing risk and reward. Below is a breakdown of how it compares using common performance measures.
Risk-Adjusted Performance Indicators
The charts below present risk-adjusted performance metrics for TME Pharma N.V. (ALTME.PA) and compare them to a chosen benchmark (^GSPC). These indicators evaluate an investment's returns against its associated risks.
Loading data...
Dividends
Dividend History
Drawdowns
Drawdowns Chart
The Drawdowns chart displays portfolio losses from any high point along the way. Drawdowns are calculated considering price movements and all distributions paid, if any.
Loading data...
Worst Drawdowns
The table below displays the maximum drawdowns of the TME Pharma N.V.. A maximum drawdown is a measure of risk, indicating the largest reduction in portfolio value due to a series of losing trades.
The maximum drawdown for the TME Pharma N.V. was 100.00%, occurring on Dec 5, 2024. The portfolio has not yet recovered.
The current TME Pharma N.V. drawdown is 99.99%.
Depth | Start | To Bottom | Bottom | To Recover | End | Total |
|---|---|---|---|---|---|---|
| -100% | Mar 8, 2017 | 1983 | Dec 5, 2024 | — | — | — |
| -2.32% | Nov 11, 2016 | 11 | Nov 25, 2016 | 7 | Dec 6, 2016 | 18 |
| -2.23% | Dec 20, 2016 | 1 | Dec 20, 2016 | 4 | Dec 27, 2016 | 5 |
| -1.82% | Jan 17, 2017 | 9 | Jan 27, 2017 | 27 | Mar 7, 2017 | 36 |
| -0.05% | Dec 7, 2016 | 1 | Dec 7, 2016 | 8 | Dec 19, 2016 | 9 |
Volatility
Volatility Chart
The chart below shows the rolling one-month volatility.
Loading data...
Financials
Financial Performance
The chart below illustrates the trends in the financial health of TME Pharma N.V. over time, highlighting three key metrics: Total Revenue, Earnings Before Interest and Taxes (EBIT), and Net Income.
Earnings Per Share
The chart presents the Earnings Per Share (EPS) performance of TME Pharma N.V., comparing actual results with analytics estimates.
Valuation
The Valuation section provides an overview of how TME Pharma N.V. is priced in the market compared to other companies in the Biotechnology industry. It includes key financial ratios that help investors assess whether the stock is undervalued or overvalued.
PS Ratio
This chart shows the Price-to-Sales (P/S) ratio for ALTME.PA relative to other companies in the Biotechnology industry. Currently, ALTME.PA has a P/S ratio of 423.6. This P/S ratio is high relative to other companies in the industry. It could mean the stock is overvalued, or that investors expect strong future growth and profitability.
PB Ratio
The chart illustrates the Price-to-Book (P/B) ratio for ALTME.PA in comparison with other companies in the Biotechnology industry. Currently, ALTME.PA has a P/B value of 4.9. This P/B ratio is in line with the industry average, suggesting the stock is valued fairly in relation to its book value.
Income Statement
| TTM | |
|---|---|
Revenue | — |
Total Revenue | — |
Cost Of Revenue | — |
Gross Profit | — |
Operating Expenses | — |
Selling, General & Admin Expenses | — |
R&D Expenses | — |
Depreciation And Amortization | — |
Total Operating Expenses | — |
Income | — |
Income Before Tax | — |
Operating Income | — |
EBITDA | — |
EBIT | — |
Earnings From Continuing Operations | — |
Net Income | — |
Income Tax Expense | — |
Other Non-Operating Income (Expenses) | — |
Extraordinary Items | — |
Discontinued Operations | — |
Effect Of Accounting Charges | — |
Non Recurring | — |
Minority Interest | — |
Other Items | — |
Interest Income | — |
Interest Expense | — |
Net Interest Income | — |